The small molecule Lenalidomide (LEN) is an inhibitor of TNF-α production.15 LEN has shown therapeutic promises in clinical trials for myeloma in consideration of its antiangiogenic and anti-inflammatory effects.16, 17, 18 Other researches have also focused on its effects in solid tumors,19, 20 but little is known about its treatment effects on OA. The gene discussed is TNF; the disease is plasma cell myeloma.